Skip to main content
SpringerLink
Log in

HER2-Positive Breast Cancer: Adjuvant and Neoadjuvant Therapy

  • Chapter
  • First Online:
Handbook of HER2-targeted agents in breast cancer

  • 571 Accesses

Abstract

So far, trastuzumab is the only anti-human epidermal growth factor receptor 2 (HER2) drug registered in the early breast cancer (EBC) adjuvant setting [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 49.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al; for the Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672.

    Google Scholar 

  2. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684.

    Google Scholar 

  3. Yin W, Jiang Y, Shen Z, Shao Z, Lu J. Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials. PLoS One. 2011;6:e21030.

    Google Scholar 

  4. Metzger-Filho O, Procter M, de Azambuja E, et al. Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. J Clin Oncol. 2013;31:1954-1960.

    Google Scholar 

  5. Hammond ME, Hayes DF, Wolff AC. Clinical Notice for American Society of Clinical Oncology- College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol. 2011;29:e458.

    Google Scholar 

  6. Perez EA, Dueck AC, McCullough AE, et al. Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst. 2012;104:159-162.

    Google Scholar 

  7. Dowsett M, Procter M, McCaskill-Stevens W, et al. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol. 2009;27:2962-2969.

    Google Scholar 

  8. Leyland-Jones B. Dose scheduling–Herceptin. Oncology. 2001;61(suppl 2):31-36.

    Google Scholar 

  9. Gianni L, Dafni U, Gelber RD, et al; for the Herceptin Adjuvant (HERA) Trial Study Team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2- positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12:236-244.

    Google Scholar 

  10. Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29:3366-3373.

    Google Scholar 

  11. Slamon D, Eiermann W, Robert N, et al; for the Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273-1283.

    Google Scholar 

  12. Perez EA, Suman VJ, Davidson NE, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011;29:4491-4497.

    Google Scholar 

  13. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab vs. neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375:377-384.

    Google Scholar 

  14. Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol. 2010;28:2024-2031.

    Google Scholar 

  15. Buzdar A, Suman VJ, Meric-Bernstam F, et al; for the Alliance for Clinical Trials in Oncology. ACOSOG Z1041 (Alliance): Definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC – P + T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P + T – FEC + T) in HER2 + operable breast cancer. J Clin Oncol. 2013 (suppl; abstr 502).

    Google Scholar 

  16. Spielmann M, Roche H, Delozier T, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol. 2009;27:6129-6134.

    Google Scholar 

  17. Arbeitsgemeinschaft Gynakologische Onkologie (AGO). Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. AGO Kommission Mama. 2012. www.ago-online. de/en/guidelines-mamma. Accessed November 11, 2013.

  18. National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology. Breast Cancer. NCCN Website. 2013. www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed November 19, 2013.

  19. Belkacemi Y, Gligorov J, Ozsahin M, et al. Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. Ann Oncol. 2008;19:1110-1116.

    Google Scholar 

  20. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al; for the Herceptin Adjuvant (HERA) Trial Study Team. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013; [Epub ahead of print].

    Google Scholar 

  21. Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol. 2009;27:5685-5692.

    Google Scholar 

  22. Pivot X, Romieu G, Debled M, Pet al; for the PHARE trial investigators. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 2013;14:741-748.

    Google Scholar 

  23. Untch M, Gelber RD, Jackisch C, et al; for the HERA Study Team. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol. 2008;19:1090-1096.

    Google Scholar 

  24. Kelly CM, Pritchard KI, Trudeau M, Andreopoulou E, Hess K, Pusztai L. Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold? Ann Oncol. 2011;22:2387-2393.

    Google Scholar 

  25. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009;27:5700-5706.

    Google Scholar 

  26. Rodrigues MJ, Albiges-Sauvin L, Wassermann J, Cottu PH. Evaluating the risk-benefit ratio of adjuvant trastuzumab-based therapy for T1a,bN0M0 HER2-positive breast carcinomas. Ann Oncol. 2011;22:2530.

    Google Scholar 

  27. Horio A, Fujita T, Hayashi H, et al. High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers. Int J Clin Oncol. 2012;17:131-136.

    Google Scholar 

  28. McArthur HL, Mahoney KM, Morris PG, et al. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer. 2011;117:5461-5468.

    Google Scholar 

  29. Mackey JR, Clemons M, Cote MA, et al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr Oncol. 2008;15:24-35.

    Google Scholar 

  30. Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with nodepositive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30:3792-3799.

    Google Scholar 

  31. Procter M, Suter TM, de Azambuja E, et al. Longer-term assessment of trastuzumabrelated cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol. 2010;28:3422-3428.

    Google Scholar 

  32. Burstein HJ, Piccart-Gebhart MJ, Perez EA, et al. Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol. 2012;30:2179-2182.

    Google Scholar 

  33. Goss PE, Smith IE, O’Shaughnessy J, et al; for the TEACH investigators. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14:88-96.

    Google Scholar 

  34. Untch M, Fasching PA, Konecny GE, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011;29:3351-3357.

    Google Scholar 

  35. von Minckwitz G, Untch M, Nuesch E, et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat. 2011;125:145-156.

    Google Scholar 

  36. Untch M, Loibl S, Bischoff J, et al; for the German Breast Group (GBG); Arbeitsgemeinschaft Gynakologische Onkologie-Breast (AGO-B) Study Group. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012;13:135-144.

    Google Scholar 

  37. Baselga J, Bradbury I, Eidtmann H, et al; for the NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379:633-640.

    Google Scholar 

  38. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25-32.

    Google Scholar 

  39. Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013; [Epub ahead of print].

    Google Scholar 

  40. Ismael G, Hegg R, Muehlbauer S, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012;13:869-878.

    Google Scholar 

  41. Food and Drug Administration (FDA). Guidance for Industry Pathologic Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval. May 2012. FDA website. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM305501.pdf. Accessed November 19, 2013.

Download references

Author information

Authors and Affiliations

  1. Breast Center, University of Munich, Munich, Germany

    Nadia Harbeck

Authors
  1. Nadia Harbeck
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Healthcare

About this chapter

Cite this chapter

Harbeck, N. (2013). HER2-Positive Breast Cancer: Adjuvant and Neoadjuvant Therapy. In: Handbook of HER2-targeted agents in breast cancer. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-907673-94-8_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-907673-94-8_3

  • Published:

  • Publisher Name: Springer Healthcare, Tarporley

  • Print ISBN: 978-1-907673-93-1

  • Online ISBN: 978-1-907673-94-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation